Plain-English translation of NCT06742892 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called HLX43 to treat advanced liver cancer in patients whose disease has not responded to standard treatments or who experienced intolerable side effects from them. The study will test three different doses of the medication to find the right balance between effectiveness and safety. Researchers want to understand how well this treatment works and how well patients tolerate it.
Many people with advanced liver cancer either do not respond well enough to current standard treatments or cannot tolerate their side effects. This medication is designed to work in a new way to help patients whose cancer has progressed despite standard therapy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive infusions of the medication every three weeks through a vein in your arm. You will continue treatment as long as your cancer responds well, you tolerate the medication without severe side effects, and you wish to continue. Throughout the study, you will have regular blood tests, imaging scans, and clinic visits so doctors can monitor how you are responding and check for any side effects. The study will continue until your cancer progresses, you need a different treatment, you experience intolerable side effects, or you choose to withdraw.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China